Emmaus Life Sciences has been granted market exclusivity for its sickle cell treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The exclusivity, awarded by NUPCO, the country’s unified procurement agency, applies to major government healthcare institutions, including hospitals under the Ministry of Health, Military Hospitals, and King Faisal Specialty Hospitals. Initially set for one year, the period may be extended to three years if Endari receives full marketing approval in KSA.

This milestone strengthens Emmaus’ global footprint in sickle cell disease treatment, expanding patient access to Endari in a key market.

At Oxydial, we commend this achievement, which highlights the growing recognition of innovative treatments for SCD and underscores the importance of expanding global healthcare access.

Read more: https://ir.emmausmedical.com/news-events/press-releases/detail/165/emmaus-life-science-reports-grant-of-endari-market

#SickleCell #Endari #EmmausLifeSciences #BiotechInnovation #RareDiseases #DrugDevelopment #HealthcareAccess #SCDTreatment